PriceTargets.com logo

NASDAQ:BOLT - Bolt Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.00
  • Forecasted Upside: 83.36 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$22.36 As of 04/16/2021 01:00 AM ET
▼ -1.97 (-8.10%)
1 month | 3 months | 12 months
Get New Bolt Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$41.00
▲ +83.36% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is $41.00, with a high forecast of $45.00 and a low forecast of $37.00. The average price target represents a 83.36% upside from the last price of $22.36.
Buy
The current consensus among 4 investment analysts is to buy stock in Bolt Biotherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021SVB LeerinkBoost Price TargetOutperform$36.00 ➝ $37.00Low
i
Rating by D. Graybosch at SVB Leerink LLC
4/6/2021SVB LeerinkBoost Price TargetOutperform$36.00 ➝ $37.00Medium
i
Rating by D. Graybosch at SVB Leerink LLC
3/8/2021SVB LeerinkInitiated CoverageOutperform$36.00N/A
i
Rating by D. Graybosch at SVB Leerink LLC
3/8/2021Morgan StanleyInitiated CoverageOverweight$45.00N/A
i
3/8/2021GuggenheimInitiated CoverageBuy$42.00N/A
i
3/8/2021Stifel NicolausInitiated CoverageBuy$40.00N/A
i
3/2/2021Morgan StanleyInitiated CoverageOverweight$45.00N/A
i
3/2/2021SVB LeerinkInitiated CoverageOutperform$36.00N/A
i
Rating by D. Graybosch at SVB Leerink LLC
3/2/2021Stifel NicolausInitiated CoverageBuy$40.00N/A
i
3/2/2021GuggenheimInitiated CoverageBuy$42.00N/A
i
(Data available from 4/18/2016 forward)
Bolt Biotherapeutics logo
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Read More

Today's Range

Now: $22.36
$21.36
$24.27

50 Day Range

MA: $30.61
$21.84
$39.93

52 Week Range

Now: $22.36
$20.87
$43.07

Volume

206,381 shs

Average Volume

310,352 shs

Market Capitalization

$812.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bolt Biotherapeutics?

The following sell-side analysts have issued research reports on Bolt Biotherapeutics in the last year: Guggenheim, Morgan Stanley, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for BOLT.

What is the current price target for Bolt Biotherapeutics?

4 Wall Street analysts have set twelve-month price targets for Bolt Biotherapeutics in the last year. Their average twelve-month price target is $41.00, suggesting a possible upside of 83.4%. Morgan Stanley has the highest price target set, predicting BOLT will reach $45.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $37.00 for Bolt Biotherapeutics in the next year.
View the latest price targets for BOLT.

What is the current consensus analyst rating for Bolt Biotherapeutics?

Bolt Biotherapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BOLT will outperform the market and that investors should add to their positions of Bolt Biotherapeutics.
View the latest ratings for BOLT.

What other companies compete with Bolt Biotherapeutics?

Other companies that are similar to Bolt Biotherapeutics include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Novavax, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Bolt Biotherapeutics' investor relations team?

The company's listed phone number is 650-665-9295. The official website for Bolt Biotherapeutics is www.boltbio.com.